FDA Recalls Generic Blood Pressure Pills: What Older Adults Need to Know

Are your daily blood pressure tablets working the way your doctor intended? Federal health regulators issued a nationwide safety alert after a generic drug manufacturer recalled 3,744 bottles of combination blood pressure medication. Routine laboratory quality testing revealed that batches of the tablets failed dissolution standards, meaning the active ingredients may not dissolve and absorb properly in the human digestive tract.

Managing hypertension requires consistent, reliable medication levels. When a maintenance prescription fails to dissolve correctly, blood pressure can rise without warning, increasing the strain on the cardiovascular system. If you or a loved one takes combination therapy for high blood pressure, here is what official inspection records show, how to read your pill bottle's label, and the exact steps to replace affected medication safely.

By the Numbers: Scope of the Nationwide Recall

The U.S. Food and Drug Administration (FDA) designated the action as a Class II recall. Under regulatory definitions, a Class II recall applies to situations where exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

The recall impacts generic Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide tablets at the 40 mg / 10 mg / 12.5 mg strength, distributed across the country by Macleods Pharma USA. The manufacturer initiated the recall after quality assurance checks identified that sample tablets did not meet dissolution rate specifications.

The total volume of 3,744 bottles is split between standard monthly supplies and extended 90-day maintenance supplies.

Source: U.S. Food and Drug Administration (FDA)

View as table

	Units Recalled
30-Count Bottles	3,528Bottles
90-Count Bottles	216Bottles

As the data illustrates, the vast majority of recalled units are packaged in 30-count bottles commonly dispensed by community retail pharmacies:

• 30-count bottles: 3,528 bottles under Lot 12251163A
• 90-count bottles: 216 bottles under Lot 12251163B
• Total units affected: 3,744 bottles
• Stated expiration date: May 31, 2027

Both lots share the same expiration date of May 31, 2027 (05/31/2027), meaning these containers could easily remain in home medicine cabinets or active daily pill organizers for months if not checked promptly.

Why Tablet Dissolution Matters for Hypertension Management

This particular medication is a fixed-dose triple combination tablet. It brings three distinct cardiovascular medications into a single daily pill:

1. Olmesartan medoxomil (40 mg): An angiotensin II receptor blocker (ARB) that prevents blood vessels from constricting.
2. Amlodipine (10 mg): A calcium channel blocker that relaxes arterial smooth muscle tissue.
3. Hydrochlorothiazide (12.5 mg): A thiazide diuretic that assists the kidneys in removing excess fluid and sodium.

In routine factory testing, laboratory analysts discovered that the olmesartan component failed dissolution testing, failing to dissolve at the required rate.

For an oral solid tablet to work, it must disintegrate and dissolve in gastrointestinal fluids so the bloodstream can absorb the active compounds. If a tablet dissolves too slowly or incompletely, the digestive tract passes the compound through before the body can absorb the full 40 mg dose of olmesartan.

For older adults, consistent medication absorption is critical. Incomplete dosing can lead to unpredictable blood pressure fluctuations or gradual spikes that do not produce obvious physical symptoms. Over time, poorly controlled hypertension increases the risk of serious cardiovascular events.

Checking Your Bottle: Lot Numbers and National Drug Codes

Before discarding any medication, inspect your container carefully. The recall is strictly limited to specific lots and packaging configurations from Macleods Pharma USA. Other strengths and manufacturers of olmesartan, amlodipine, and hydrochlorothiazide are not included in this recall.

Examine the product label on your amber prescription container or original manufacturer bottle for the following identifying details:

Medication Name & Strength	Package Size & Quantity	Specific Lot Number	National Drug Code (NDC)	Expiration Date
Olmesartan / Amlodipine / HCTZ 40 mg / 10 mg / 12.5 mg	30-Count Bottle (3,528 units)	12251163A	33342-246-07	05/31/2027
Olmesartan / Amlodipine / HCTZ 40 mg / 10 mg / 12.5 mg	90-Count Bottle (216 units)	12251163B	33342-246-10	05/31/2027

If your pharmacy affixed its own store label directly over the manufacturer's label, the lot number and NDC might be printed along the bottom edge, side margin, or receipt paperwork. If you cannot locate these numbers, your dispensing pharmacy can verify your batch number in their electronic dispensing system.

International Comparison: How Other Health Systems Handle Dissolution Defects

Quality control failures involving dissolution rates are not unique to the United States pharmaceutical supply chain. Overseas regulatory authorities maintain structured notification protocols to contain manufacturing variances before they affect patient care.

In the United Kingdom, for example, the Medicines and Healthcare products Regulatory Agency (MHRA) manages a four-tier alert system for defective medicinal products. When batches exhibit dissolution irregularities or manufacturing defects that do not present an immediate life-threatening danger, the MHRA issues a Class Two drug alert.

Much like the FDA's Class II designation, a UK Class Two alert mandates community pharmacists and hospital dispensaries to immediately halt dispensing, quarantine affected packages, and return them to distributors. In the National Health Service (NHS) framework, this process is engineered to secure prescription supplies at the dispensary counter so that patients receive replacement medication from unaffected batches without interrupting their chronic illness therapies.

Practical Steps: What Patients Should Do Today

If you discover that your prescription bottle matches the recalled lot numbers, healthcare professionals stress that you should take measured steps rather than stopping your treatment on your own.

Halting blood pressure medications suddenly can trigger dangerous rebound spikes in blood pressure. Because the issue involves slow dissolution rather than dangerous contamination or toxic adulteration, continuing your daily routine while arranging an immediate exchange is the standard medical recommendation.

Use the following practical checklist to resolve the issue:

• ☐ Inspect your pill bottle: Check your current bottle for lot number 12251163A (30-count) or 12251163B (90-count), NDC 33342-246-07 or 33342-246-10, and an expiration date of 05/31/2027.
• ☐ Do not stop treatment abruptly: Continue taking your prescribed dose until you have a replacement container in hand, unless your doctor specifically instructs otherwise.
• ☐ Contact your dispensing pharmacy: Call the retail or mail-order pharmacy that filled the prescription. Explain that your bottle is subject to the Macleods Pharma USA Class II recall; pharmacists can provide an unaffected batch or equivalent substitute.
• ☐ Verify your online safety alerts: If you use mail-order services or cannot reach your local pharmacist immediately, review the official recall listing online at fda.gov/safety/recalls.
• ☐ Notify your prescribing physician: If you experienced unexpected blood pressure readings or mild symptoms while taking tablets from the affected lots, notify your doctor's office so they can review your treatment logs.

By reviewing your bottle markings and contacting your pharmacist, you can replace defective lots promptly and maintain consistent cardiovascular protection.

This article is based on official FDA enforcement reports and regulatory recall notifications published in November 2026. For specific questions regarding your blood pressure regimen or individual cardiovascular care, consult your prescribing physician or dispensing pharmacist.

Sources

• U.S. Food and Drug Administration (FDA), "Recalls, Market Withdrawals, & Safety Alerts: Macleods Pharma USA" https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
• NBC 5 Chicago, "FDA issues nationwide recall of blood pressure medication after pills fail quality test" https://www.nbcchicago.com/news/health/fda-blood-pressure-medication-recall-2026